STOP-HAE: A Phase 3 Study of ADX-324 in HAE

ClinicalTrials.gov ID: NCT06960213

Public ClinicalTrials.gov record NCT06960213. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

STOP-HAE: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate the efficacy and safety of ADX-324 in participants with Type 1 or Type 2 hereditary angioedema. The study will also evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), and health-related quality of life measures.

Study identification

NCT ID: NCT06960213
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: ADARx Pharmaceuticals, Inc.; Industry
Enrollment: 90 participants

Conditions and interventions

Conditions

Interventions

ADX-324 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 28, 2025 (Actual)
Primary completion: Nov 30, 2027 (Estimated)
Completion: Dec 31, 2027 (Estimated)
Last update posted: Sep 10, 2026

2025 – 2027

United States locations

U.S. sites: 19
U.S. states: 12
U.S. cities: 19

Facility	City	State	ZIP	Site status
ADARx Clinical Site	Litchfield Park	Arizona	85340	Recruiting
ADARx Clinical Site	Scottsdale	Arizona	85251	Recruiting
ADARx Clinical Site	Little Rock	Arkansas	72205	Recruiting
ADARx Clinical Site	San Diego	California	92122	Recruiting
ADARx Clinical Site	Santa Monica	California	90404	Not yet recruiting
ADARx Clinical Site	Walnut Creek	California	94598	Recruiting
ADARx Clinical Site	Centennial	Colorado	80112	Recruiting
ADARx Clinical Site	Orlando	Florida	32807	Recruiting
ADARx Clinical Site	Chevy Chase	Maryland	20815	Recruiting
ADARx Clinical Site	Wheaton	Maryland	20902	Withdrawn
ADARx Clinical Site	Detroit	Michigan	48202	Recruiting
ADARx Clinical Site	St Louis	Missouri	63141	Recruiting
ADARx Clinical Site	Las Vegas	Nevada	89128	Recruiting
ADARx Clinical Site	New York	New York	10029	Recruiting
ADARx Clinical Site	Cincinnati	Ohio	45236	Recruiting
ADARx Clinical Site	Cleveland	Ohio	44195	Not yet recruiting
ADARx Clinical Site	Columbus	Ohio	43235	Withdrawn
ADARx Clinical Site	Toledo	Ohio	43617	Recruiting
ADARx Clinical Site	Hershey	Pennsylvania	17033	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06960213, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 10, 2026 · Synced Oct 24, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06960213 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →